Amgen's new drug could mean fewer shots for obesity patients

Amgen's MariTide that is now in Phase 3 trials could cut weekly weight-loss injections to as few as four a year.

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.